Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03482882 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
A Phase 2 study of Treatment of Depression in Adults With Parkinson's Disease (PD), sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
- 20
- Study locations
NCT03482882 is a Phase 2 study of Treatment of Depression in Adults With Parkinson's Disease (PD) that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 47 participants. The trial reports 20 study locations across 10 states.
The verdict
NCT03482882, a Phase 2 study of Treatment of Depression in Adults With Parkinson's Disease (PD), has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy of pimavanserin for the treatment of depression in adults with Parkinson's disease.
Conditions Studied
Interventions
- DRUG Pimavanserin
Study Locations (20)
California
- ATP Clinical Research, Inc. - Costa Mesa
- The Parkinson's and Movement Disorder Institute - Fountain Valley
- SC3 Research-Reseda - Pasadena
- The Neurology Group - Pomona
- SC3 Research-Reseda - Reseda
- CNS Network - Torrance
Florida
- Parkinson's Disease and Movement Disorder Center of Boca Raton - Boca Raton
- University of Florida - Gainesville
- Parkinson's Disease Treatment Center of SW Florida - Port Charlotte
- Infinity Clinical Research, LLC - Sunrise
- Tallahassee Neurological Clinic, P.A. - Tallahassee
New York
- Albany Medical College - Albany
- David L. Kreitzman, MD, PC - Commack
Connecticut
- Associated Neurologists, P.C. - Danbury
Michigan
- SRI Biosciences, Clinical Trials and Strategic Development Services - Plymouth
Missouri
- Washington University School of medicine - St Louis
New Jersey
- Bio Behavioral Health - Toms River
North Carolina
- Asheville Neurology Specialists, PA - Asheville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2018-03-09 |
| Est. Completion | 2019-07-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03482882
The ClinicalTrials.gov registry entry for NCT03482882 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Treatment of Depression in Adults With Parkinson's Disease (PD) appearing as the primary indexed condition, and to 1 intervention - of which Pimavanserin is the first listed.
NCT03482882 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT03482882 about?
NCT03482882 is a clinical study titled "Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression". The purpose of this study is to assess the efficacy of pimavanserin for the treatment of depression in adults with Parkinson's disease.
What is the current status of trial NCT03482882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2018-03-09. Estimated completion is 2019-07-24.
What conditions does trial NCT03482882 study?
This clinical trial studies the following conditions: Treatment of Depression in Adults With Parkinson's Disease (PD).
What interventions are being tested in trial NCT03482882?
The interventions under investigation include: Pimavanserin (DRUG).
Who is sponsoring clinical trial NCT03482882?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03482882 being conducted?
This trial has 20 study locations across California, Connecticut, Florida, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.